Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI
June 26, 2026 08:00 AM EDT
How one biotech is using 'digital twins' to study a muscle disease therapy
Lei Lei Wu
News Reporter
Epicrispr Biotechnologies on Friday shared an early cut of data from its study of an epigenetic editing therapy for a genetic disease that leads to …
Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321
Gene-editing startups are using CRISPR to treat diseases
CRISPR’s next act: the companies editing the epigenome to treat disease
Embryo editing advances reignite ethical debates
Abu Dhabi pushes ahead in genomics with landmark gene-editing partnership
Next-gen CRISPR tools improve editing accuracy in embryos, but also stoke ethical concerns
Daily briefing: Editing the epigenome with CRISPR to treat disease
AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high…
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
Tune Therapeutics' new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections.
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a…
